Window Shopping: Rheumatoid Arthritis Biosimilars On Show At ACR
Clinicians in the US can’t buy in to anti-TNF biosimilars yet, but wave of equivalence data featured at American College of Rheumatology meeting gives them a chance to evaluate products before they hit the market.
You may also be interested in...
Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.